Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million. | Novavax will remain headquartered at ...

Novavax (NVAX) ended the recent trading session at $8.46, demonstrating a -1.51% change from the preceding day's closing price. This change lagged the S&P 500's 0.53% loss on the day. Meanwhile, the ...

Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in scaling up ...

Assignment of the lease for the facility and sale of assets are expected to close in January and result in $40 million in payments to Novavax, while the sale of property adjacent to the headquarters ...

Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's ...

If you'd invested $10,000 in Novavax (NVAX 2.11%) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant that, ...

Novavax will announce its Q1 2024 earnings this Friday, 10th May. The company reported revenues of $476m, $1.15bn, $1.98bn, and $984m in the four years since 2020, with heavy net losses in each of ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...